Secondary Logo

Institutional members access full text with Ovid®

Effect of lingual nerve block on burning mouth syndrome (stomatodynia): A randomized crossover trial

Grémeau-Richard, Christelleb,e,*; Dubray, Claudec,e; Aublet-Cuvelier, Brunod,e; Ughetto, Sylvied,e; Woda, Alaina,e

doi: 10.1016/j.pain.2009.11.016

Burning mouth syndrome (stomatodynia) is associated with changes of a neuropathic nature the main location of which, peripheral or central, remains unknown. A randomised, double-blind crossover design was used to investigate the effects of lingual nerve block on spontaneous burning pain and a possible correlation with the effects of topical clonazepam, the patient's response to a psychological questionnaire, and the taste and heat thresholds. The spontaneous burning was measured with a visual analogue scale (VAS) just before and 15 min after injection. The decreases in VAS score after lidocaine or saline injection were not significantly different (2.7 ± 3.9 and 2.0 ± 2.6, respectively; n = 20). However, two groups of patients could be identified: in a “peripheral group” (n = 10) the VAS decrease due to lingual nerve injection was 4.3 ± 3.1 cm after lidocaine and 0.9 ± 0.3 cm after saline (p = 0.02). In a “central group” (n = 7), there were an increase in pain intensity score (−0.8 ± 2.6 cm) after lidocaine and a decrease (1.5 ± 3.0 cm) after saline (p = 0.15). An increase in the hospital anxiety and depression (HAD) score and a decreased taste sensitivity and heat pain threshold of painful oral area were seen in patients compared with age-and-sex-matched controls (p < 0.05). Topical clonazepam treatment tended to be more effective (p = 0.07) and HAD score lower (p < 0.03) in the peripheral than in the central group. These results suggest that the neuropathic disorder associated with stomatodynia may be predominantly peripheral, central or mixed depending on the individual. Topical application of clonazepam and HAD may serve as indicators of which mechanism is dominating.

aEA 3847, Faculté de Chirurgie Dentaire, Université d'Auvergne, 63000 Clermont-Ferrand, France

bInserm U 929, Clermont-Ferrand, France

cCentre de Pharmacologie Clinique, CHU, Clermont-Ferrand, France

dDépartement d'Information Médicale, CHU, Clermont-Ferrand, France

eCHU, Clermont-Ferrand, Hôtel-Dieu, F-63001 Clermont-Ferrand, France

*Corresponding author. Address: Inserm U 929, Université d'Auvergne, U.F.R. d'Odontologie, 11, Boulevard Charles-de-Gaulle, 63000 Clermont-Ferrand, France. Tel.: +33 4 73 17 73 11; fax: +33 4 73 17 73 89.


Submitted February 11, 2009; revised October 13, 2009; accepted November 13, 2009.

© 2010 Lippincott Williams & Wilkins, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website